Scientists probe Cholesterol's role in brain decline

NCT ID NCT07207486

Recruiting now Knowledge-focused Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how cholesterol and its byproducts relate to different types of dementia, including Alzheimer's and frontotemporal dementia. Researchers will measure these substances in brain tissue, spinal fluid, and blood from 80 adults aged 40-85. The goal is to find patterns that could help diagnose or track dementia progression, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia frontotemporal dementia neurodegenerative disease tauopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEMENTIAS NEURODEGENERATIVE DEMENTIA

Contacts and locations

Locations

Fondazione IRCCS Istituto Neurologico Carlo Besta
RECRUITING

Milan, 20133, Italy
Università di Torino AOU San Luigi Gonzaga
WITHDRAWN

Torino, to, 10043, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.